ACDM Conference 2017 - Overview of Keynotes


ACDM Annual Conference
Tuesday 14th March 2017

Husa President Park Hotel, Brussels

Early bird rates available for limited period

The ACDM 2017 Annual Conference is pleased to have two significant keynote speakers joining us for this year’s conference in Brussels. Together they will motivate, inspire and challenge you, giving you confidence and vision to help build a successful Clinical Data Management future for your companies.

Andy Lawton

Andy Lawton – Consultant and director of Risk Based Approach Ltd and former Global Head of Clinical Data Management for Boehringer Ingelheim, Andy has extensive experience in computing, statistics, data management, RDE/RDC, system design, RBA in CSV and clinical trials.  One of the founding committee members of ACDM, he won “best author of the year 2015 and 2016” from the DIA, for the TransCelerate papers on SDV and central monitoring in the TIRS Journal produced while a member of the TransCelerate RBM work stream. 
Andy will challenge what you think you know about the recent ICH E.6 (GCP) Addendum, highlighting its importance as more than just clarifications surrounding the use of Risk Based Monitoring. He will cause you to have a fundamental re-think on how we address quality in our clinical trials, focusing on the impact of the changes on CDM and how we incorporate these into our processes.
Medecins Sans Frontieres
The second keynote joins us from charity organisation Médecins Sans Frontières (Doctors without Borders). MSF is an international, independent, medical humanitarian organisation that delivers emergency aid to people affected by armed conflict, epidemics, natural disasters and exclusion from healthcare. MSF offers assistance to people based on need, irrespective of race, religion, gender or political affiliation. During the course of this support MSF occasionally becomes involved in clinical trials, for example in 2015 Médecins Sans Frontières (MSF)’s ELWA 3 Ebola Management Centre in Monrovia, Liberia hosted a University of Oxford led clinical trial which assessed the effect of a two week course of brincidofovir on patients at the centre diagnosed with the Ebola virus. MSF supported two further trials in Guinea during the same outbreak: Experimental Treatment with Favipiravir for Ebola Virus Disease, and Evaluation of Convalescent Plasma for Ebola Virus Disease. A representative will join us to share their experiences and give us an insight into these trials and the work they do in the extreme environments they are often faced with.

To book your place please click hereThe early bird deadline closes on the 27th January 2017.

Look forward to seeing there

Kind regards 

ACDM Conference Committee

« News Menu